Scientists United Against Tropical Diseases.
We're joined by an expertise in diagnostics AND A PASSION TO MAKE A DIFFERENCE.
DDTD was established in 2011, stemming from a long-standing desire to tackle diseases that are not adequately addressed. We have assembled a high-quality team composed of industrial scientists and academic experts. We are modeled similar to other successful biotech start-ups. Our board of directors consists of leaders with demonstrated success in both start-ups and in established companies.
We are passionate about serving the needs of the underprivileged within our capacity as scientists. In addition, we believe it is important to increase public awareness - especially within our local San Diego community - of the dire need to improve global health. The community’s resulting civic engagement can make an impact globally and DDTD wants to lead these efforts.
Board of Directors
Marco A. Biamonte, President. Marco holds a Ph.D. in organic chemistry from the University of Cambridge, UK, and performed post-doctoral studies at the Swiss Institute for Technology (ETH-Z). Marco worked as a medicinal chemist in the pharmaceutical industry for 14 years, mostly in oncology. He co-led up to 3 projects simultaneously in 3 different therapeutic areas and managed up to 12 chemists. He and his colleagues have had success in advancing 2 new drugs into clinical trials (BIIB-021 and BIIB-028, respectively in Phase II and Phase I). In 2011, motivated by a long-standing desire, Marco created DDTD.
Beverly Coyne, Secretary. Beverly Coyne has worked at Qualcomm Technologies for the past eight years and is the Chair for Diversity Employee Network QAAAD. Prior to joining Qualcomm, she held leadership positions in Investor and Public Relations with Ligand Pharmaceuticals, Wingcast International and Natural Alternatives International. Ms. Coyne has served on the board for the San Diego branch of the National Investor Relations Institute (NIRI). She is a former Sergeant in The United States Marine Corps and was at that time the youngest Marine in the Corps and one of the first women to complete Radio Operators training going on to train as an Air Traffic Controller.
Vish Gaitonde, Treasurer. Vish Gaitonde is a senior Information Technology executive, currently Director, Product Strategy, at Oracle Corporation. His 25 year career has encompassed leadership and management roles in Product Strategy, Strategic Alliances, and Business Development. Vish has a B. Eng. from University of Mumbai (India), and M.S., in Management, from Clemson University. He is credentialed and affiliated with professional organizations in the fields of Configuration Management (CMI), New Product Development (PDMA), Supply Chain Management (APICS) and Program Management (PMI).
Jutta Wanner, Board Member. Jutta reinforces the strength in early drug discovery efforts. She is currently Vice President of Chemistry at Coferon (2013-present). She previously headed one of the medicinal chemistry departments at Roche, NJ (2004-2013) where she specialized in the early discovery phases in oncology, inflammation and virology. She received her PhD from the University of Kansas and performed her postdoctoral training at The Scripps Research Institute (San Diego, CA).
Robert Epple, Board Member. Robert brings in expertise in drug design. Robert was previously the Associate Director at the Genomics Institute of the Novartis Research Foundation (GNF, San Diego, 2000-present). He has worked on many diverse projects and delivered several clinical candidates. Robert completed his Ph.D. at the Swiss Institute of Technology (ETH-Z), and performed post-doctoral studies in the group of Nobel Laureate Barry Sharpless at the Scripps Research Institute (San Diego, CA).